Filing Details

Accession Number:
0001209191-18-050736
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-12 21:00:19
Reporting Period:
2018-09-10
Accepted Time:
2018-09-12 21:00:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1600132 Bellerophon Therapeutics Inc. BLPH () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1277994 P L Iv Fund Entrepreneurs Venrock C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1277997 P L Iv Associates Venrock C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1305238 Venrock Management Iv, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1305239 Venrock Partners, L.p. C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1305240 Venrock Partners Management, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1305243 Vef Management Iv, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1602263 Vhcp Management Ii, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1602264 Venrock Healthcare Capital Partners Ii, L.p. C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1615979 Y Bong Koh C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
1615983 Vhcp Co-Investment Holdings Ii, Llc C/O Venrock
3340 Hillview Avenue
Palo Alto CA 94304
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-10 200,000 $1.22 6,901,163 No 4 P Indirect By funds
Common Stock Acquisiton 2018-09-11 200,000 $1.14 7,101,163 No 4 P Indirect By funds
Common Stock Acquisiton 2018-09-12 75,000 $1.15 7,176,163 No 4 P Indirect By funds
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By funds
No 4 P Indirect By funds
No 4 P Indirect By funds
Footnotes
  1. This Form 4 is the first of two Form 4s being filed to report the beneficial ownership of the following Reporting Persons: Venrock Associates IV, LP, Venrock Partners, LP, Venrock Entrepreneurs Fund IV, LP, Venrock Management IV, LLC, Venrock Partners Management, LLC, VEF Management IV, LLC, Venrock Healthcare Capital Partners II, LP, VHCP Management II, LLC, VHCP Co Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, LP, VHCP Management III, LLC, VHCP Co Investment Holdings III, LLC, Bong Koh and Nimish Shah. Two Form 4s are being filed because each form can report a maximum of 10 reporting persons.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.2099 to $1.2265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  3. Consists of (i) 181,820 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 18,180 shares purchased by VHCP Co-Investment Holdings III, LLC.
  4. Venrock Management IV, LLC ("VM4") is the general partner of Venrock Associates IV, LP. Venrock Partners Management, LLC ("VPM") is the general partner of Venrock Partners, LP. VEF Management IV, LLC ("VEFM") is the general partner of Venrock Entrepreneurs Fund IV, LP. VHCP Management II, LLC ("VHCPM2") is the general partner of Venrock Healthcare Capital Partners II, LP and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC ("VHCPM3") is the general partner of Venrock Healthcare Capital Partners III, LP and the manager of VHCP Co-Investment Holdings III, LLC. Bong Koh and Nimish Shah are the managing members of VHCPM2 and VHCPM3. Each of VM4, VPM, VEFM, VHCPM2, VHCPM3, Bong Koh and Nimish Shah (together, the "Managers") may be deemed to beneficially own these shares. Each of the Managers expressly disclaims beneficial ownership over these shares except to the extent of their indirect pecuniary interests therein.
  5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10894 to $1.1990, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  6. Consists of (i) 68,183 shares purchased by Venrock Healthcare Capital Partners III, LP and (ii) 6,817 shares purchased by VHCP Co-Investment Holdings III, LLC.